Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

J Allergy Clin Immunol Pract. 2021 Mar;9(3):1389-1392.e2. doi: 10.1016/j.jaip.2020.09.042. Epub 2020 Oct 7.

Affiliations

¹ Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: [email protected].
² Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands.
³ Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.

PMID: 33038589
DOI: 10.1016/j.jaip.2020.09.042

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized
Conjunctivitis* / drug therapy
Dermatitis, Atopic* / drug therapy
Follow-Up Studies
Humans
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab